BioCentury
ARTICLE | Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

BioCentury’s analysis of ASCO 2019 abstracts shows bispecifics outpacing CAR Ts in solid tumors

June 1, 2019 2:43 AM UTC

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via new strategies.

BioCentury’s fourth annual survey of abstracts at the American Society of Clinical Oncology (ASCO) meeting presents a snapshot of clinical research in cancer, according to a machine learning-based analysis of 4,627 abstracts for mentions of products, indications, targets, modalities or other hot topic terms...